Document is current
Any future updates will be listed below
-
Authors
Chang, Zhibin
Li, Mingming
Sun, Zhicheng
Liu, Zhaogang
Yang, Yue
Xu, Lei
Li, Lei
Zhang, Chengsheng
Sun, Pengfei
Zhong, Jingtao
Zhang, Bo
Shi, Xuetao
Cui, Kai
Zhang, Jianxin
Li, Zhongchao
Zhao, Lei
-
Funding
Funding for this research was provided by:
National Natural Science Fund of China (81872400)
The Key Research and Development Program of Shandong (2021SFGC0501)
Joint Innovation and Development Item of Shandong Natural Scientific Fund (ZR2021LZL008)
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 9 October 2024
First Online: 17 October 2024
Declarations
:
: The study was approved by the Ethics Committee of Shandong Cancer Hospital affiliated to Shandong First Medical University, but informed consent needed to be waived for three reasons: First, the study lasted a long time; Second, it does not involve patient privacy information; In addition, this was a retrospective study and it did not interfere with treatment decisions.
: Not Applicable.
: Not applicable.
: L.Z. is on the speakers’ bureau for Bayer, MSD, AstraZeneca, Roche, BeiGene, Innovent, Junshi Biosciences and Hengrui Medicine. The remaining authors declare no competing interests.
